Search Results

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

Anderson Area Cancer Center and OneOncology announced a finalized partnership to enhance the delivery of cancer services in and around Anderson, South Carolina.

Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives.

Renovaro Inc. and the Amsterdam UMC Cancer Center announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy.

Robert L. Ferris, MD, PhD, a head and neck surgical oncologist, leading expert in cancer immunotherapy and cancer center chief executive, has been named the executive director of UNC Lineberger Comprehensive Cancer Center, and UNC system chief of oncology services, effective October 1st, announced UNC School of Medicine Dean Wesley Burks, MD.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

Kannalife Sciences, Inc. is pleased to announce it has been awarded funding of $1,493,409 million from The Michael J. Fox Foundation for Parkinson’s Research.

Salarius Pharmaceuticals Inc. today announced a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center.

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the late-stage pipeline for this neuropsychiatric disorder.